Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul ... News-Medical.net When we combined mTOR inhibitor treatment with a low-dose arsenic trioxide, the combination prevented tumor cells from increasing their levels of PML in response to the mTOR inhibitors. This caused tumor cell death and blocked the growth of GBMs in ... |
